T
Talazoparib
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Active ingredient: Talazoparib
General information
Subsidy Information and Financing Scheme
[MSHL] Talazoparib Capsule 0.25 mg, 1 mg
Treatment of germline BRCA-mutated, HER2 negative, locally advanced or metastatic breast cancer in patients previously treated with chemotherapy.
Drug Guidance for Subsidy
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended talazoparib in combination with enzalutamide for inclusion on the MOH List of Subsidised Drugs for treating homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. The decision was based on the low clinical need, uncertain or unfavourable cost-effectiveness compared with treatment alternatives, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for talazoparib plus enzalutamide are provided in the Annex.
The Ministry of Health’s Drug Advisory Committee has recommended:
Olaparib 100 mg and 150 mg tablets for treating germline BRCA-mutated, human epidermal growth factor receptor (HER2) negative, locally advanced or metastatic breast cancer in patients who have been previously treated with chemotherapy.
Subsidy status
[R] Olaparib 100 mg and 150 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 September 2022.
[NR] MAF assistance does not apply to olaparib 50 mg capsules or any formulations or strengths of talazoparib for treating BRCA-mutated, HER2-negative advanced breast cancer.
Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Capsule 0.25 mg |
|
Capsule 1 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.